Mabylon AG

About Mabylon AG

Mabylon AG is a Swiss biotechnology company focused on discovering and engineering novel antibody therapeutics in allergy, inflammation, and neurology. Leveraging its technology platform and unique know-how, the company aims to create high-quality antibody libraries against validated targets to select the best functional, therapeutically relevant products.

Products & Services

Engineered Antibodies:Antibody therapeutics targeting immunology, inflammation (I&I), and neurology, developed using B-cell screening technologies and high-throughput antibody-expression platforms.

Specialties

Antibody Therapeutics Allergy Inflammation Neurology B-cell Screening Technologies High-throughput Antibody-expression Platforms

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Equity and Convertible Loan T: - FT: Equity and Convertible Loan	A: 37000000 MR: - FA: CHF 30 million FAN: 37000000	D: 2025-08-12 FD: 2025-08-12	1 investors
2	RT: Grants T: - FT: Grants	A: 1456000 MR: - FA: more than CHF 1.3 million FAN: 1456000	D: 2024-09-24 FD: 2024-09-24	3 investors

Equity and Convertible Loan Latest

2025-08-12

$37.0M

1 investor (Pro only)

Grants 2024-09-24

$1.5M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Alcide Barberis

CEO

N

Niccolò Pengo

Chief Scientific Officer

P

Peter Lichtlen

Chief Medical Advisor

T

Tiziana Sonati

Chief Operating Officer

N

Natascha Wuillemin

Executive Vice President Immunology

D

Dimitri Bieli

Executive Vice President Molecular Biology

View 14 more team members with Pro

Unlock Full Team Directory

Recent News

Mabylon AG Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised